Apixaban - Articles and news items


BMS and Pfizer announce new data for Eliquis (apixaban)

Industry news / 11 December 2015 / Victoria White

In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)…


NICE guidance recommends anti-blood clotting drug apixaban

Industry news / 9 June 2015 / NICE

NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism (VTE) in adults…

Bristol Myers Squibb logo
Bristol Myers Squibb logo
Pfizer logo

ELIQUIS® (apixaban) receives positive opinion from CHMP

Industry news, News / 24 September 2012 / Pfizer

For the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation…

Bristol Myers Squibb logo

Bristol-Myers Squibb & Pfizer receive response from FDA for ELIQUIS® (apixaban)

Industry news, News / 26 June 2012 / Bristol-Myers Squibb Company / Pfizer

Additional information requested from ARISTOTLE trial results…

Pfizer logo

New data presented on Phase 3 trial of ELIQUIS® (apixaban)

Industry news, News / 13 November 2011 / Pfizer

Bristol-Myers Squibb Company and Pfizer Inc. announced the results of the Phase 3 ADOPT trial…

Bristol Myers Squibb logo

ELIQUIS® (apixaban) superior to Warfarin for the reduction of stroke or systemic embolism

Industry news, News / 28 August 2011 / Bristol-Myers Squibb Company, Pfizer

Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial…

Pfizer logo

ELIQUIS® (apixaban) approved in Europe for preventing venous thromboembolism

Industry news, News / 20 May 2011 / Bristol-Myers Squibb Company

The European Commission has approved ELIQUIS® in the 27 countries of the EU…

Pfizer logo

Apixaban statistically superior to aspirin in reducing the composite of stroke or systemic embolism

Industry news, News / 10 February 2011 / Pfizer

Bristol-Myers Squibb Company and Pfizer Inc. announce the publication of their AVERROES study of apixaban in The New England Journal of Medicine…

APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued

Industry news, News / 18 November 2010 / BUSINESS WIRE

Companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...